Health Care & Life Sciences » Biotechnology | Mirati Therapeutics Inc.

Mirati Therapeutics Inc.

Mirati Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
Market Cap
$4.08 B
Shares Outstanding
38.15 M
Public Float
33.55 M


9393 Towne Centre Drive
San Diego California 92121
United States
Employees -
Updated 07/08/2019
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.


View All

Charles M. Baum
President, Chief Executive Officer & Director
Rodney W. Lappe
Executive Chairman